Natera, Inc. (NTRA) is a leading genetic testing and diagnostics company. Established in 2004 and headquartered in San Carlos, California, the company holds a significant position in the field of reproductive health and oncology. Natera is one of the pioneering entities in applying artificial intelligence (AI) and bioinformatics to reproductive health and cancer, enhancing disease management through genetic testing.
Natera offers a range of high-quality genetic testing services, each designed to provide critical health information. These tests assist healthcare professionals in managing their patient's health more effectively. Notably, they have developed non-invasive prenatal tests (NIPT), which can detect fetal chromosomal abnormalities as early as nine weeks into the pregnancy. Additionally, Natera offers genetic-carrier screening and advanced diagnostic services involving miscarriages and failures in vitro fertilization (IVF).
The company's innovative approach is also reflected in the field of oncology. They developed a kidney transplantation rejection test, and more recently, the company introduced the Signatera test, a personalized and tumor-informed DNA test used for the early detection of cancer recurrence.
Natera's team, made up of top data scientists, laboratory scientists, software engineers, and clinical professionals, are committed to improving patient care and outcomes through cutting-edge genetic testing. Their mission is to change the face of management in disease through genetic testing, using innovation as their springboard.
The company is marked also by its commitment to research and development. They have over 200 issued patents and collaborations with leading academic institutions to develop, validate, and broaden the clinical application of its tests.
As of 2019, Natera operates in over 50 countries and continues to grow its international presence. Natera's shares are traded on the NASDAQ Stock Market under the ticker symbol "NTRA".
In summary, Natera, Inc. is a global company that continues to redefine genetic testing in reproductive health and cancer. Its innovative and personalized approach to diagnostics not only improves patient care but also positions Natera as a leader in the drive toward precision medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Natera and Incyte have announced a collaboration on an interventional Phase II study focusing on colorectal cancer. The details of the study, including its design and specific objectives, were not fully provided in the snippet, but it signifies a joint effort in advancing cancer diagnostics and treatment.
Natera's stock fell 14.6% after the company released its third-quarter results, which showed revenue beating estimates but a wider-than-expected loss per share. The company increased its 2026 revenue forecast and aims to double revenue by 2029, but also indicated rising operating costs due to increased investment. This significant drop was notably larger than those experienced by comparable companies and Natera's own historical single-session movements.
Natera Inc. shares plunged after the genetic testing company reported mixed third-quarter results. While revenue and guidance surpassed estimates, the loss per share was wider than analysts expected. The company did raise its 2026 revenue outlook and announced a leadership change, with Solomon Moshkevich becoming CEO.
DraftKings Inc. (NASDAQ: DKNG) shares dropped significantly in pre-market trading after reporting worse-than-expected Q3 financial results and cutting its FY26 sales guidance. The company posted $1.329 billion in revenue, missing estimates, and an adjusted loss of 53 cents per share, wider than anticipated. Several other major stocks, including Atlassian (NASDAQ: TEAM) and Natera (NASDAQ: NTRA), also experienced declines following their respective quarterly earnings reports or guidance reductions.
Natera Inc. reported strong Q3 2026 results with revenue jumping 34% year-over-year to $794 million and processing a record 1.1 million tests. The company raised its full-year 2026 revenue guidance to over $3 billion and set an ambitious long-term goal to double revenues to $6 billion by 2029. Despite increased operating expenses for R&D and early cancer detection, management expressed confidence in achieving its targets through core oncology growth, global expansion, and pharma partnerships.